Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cantargia AB ( (SE:CANTA) ) has issued an announcement.
Cantargia AB’s Annual General Meeting resulted in several key decisions, including no dividend distribution, board member and CEO discharge from liability, and the re-election of board members and auditors. The meeting also approved a long-term incentive scheme for senior executives, an employee option program, and authorized the board to issue new shares up to 10% of the current outstanding shares. These resolutions aim to strengthen Cantargia’s operational framework and support its strategic growth initiatives in the biotechnology sector.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. The company has established a platform based on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. Cantargia’s oncology program, featuring the antibody nadunolimab (CAN04), is primarily studied in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Additionally, Cantargia is developing CAN10 for autoimmune and inflammatory diseases, targeting conditions like hidradenitis suppurativa and systemic sclerosis.
Average Trading Volume: 898,919
Current Market Cap: SEK388.8M
See more data about CANTA stock on TipRanks’ Stock Analysis page.